Description

Leading expert in HTA, Value & Access, Pricing, Business, with over 25 years’ experience at corporate and affiliate levels in pharma, biotech, diagnostics

Continuous track record in developing and executing EU strategies and tactics throughout product life cycle, from early stage till generic/biosimilar entry

Worked in primary care, hospital care in areas of gene therapy, CAR-T cells, oncology, neurology, ophthalmology, muscle degeneration diseases, ultra-orphan drugs/ rare diseases, diabetes cardiovascular, and woman health

Industry field of expertise

Languages

French
Native or bilingual
English
Native or bilingual
Spanish
Native or bilingual

Workplace preferences

Can work on-site

Paris (up to 50km)

AccessMinds
president
CONSULTING AND AUDITS
April 2020 - Today (6 years and 2 months)
Paris, France
Freelance contractor and consultant working with > 40 French/EU/Global partners

- Act as interim French P&MA Director, part of Executive Committees
- Prepare reimbursement, early advice submissions, hearings to HTA agency
- Develop pricing strategy and conduct direct negotiations with pricing authorities
- Secure regional product launches by implementing EU access readiness plans
- Support Global P&MA heads in the development of tools, governance, strategy
- Shape diagnostic policy environment to shift reimbursement paradigm
- Facilitate ad boards, collective intelligence workshops, and strategic meetings
- Coach and mentor newly appointed affiliate and corporate P&MA directors
CEPS price negotiation value messages resilence collaboration communication influence market access payers strategy ultra rare diseases pragmatisme enthusiasm Loyalty authenticity kindness Communication interne Metodología Agile Intellectually Curious intuitive committed performance-driven solution-seeker Decision maker anticipate Structure positive energy Flexibility
Roche
Business Unit Director - French Precision Medicine in Oncology
PHARMACEUTICALS INDUSTRY
July 2017 - December 2019 (2 years and 5 months)
Paris
Responsible for genomic profiling business in France - 4M $ sales in 2019

- Took responsibility for country P&L with a budget of over 1M$
- Launched US-based NGS services in a market led by strong in-house platforms
- Led interactions at major hospitals with finance directors, biologists, oncologists
- Piloted field model with medical, commercial and access project responsibilities
- Unite a diverse team of 12 in a challenging newly restructured organization
business unit direct profilage genomique genomic profiling precision medicine P&L team leader new business biomarkers business vision business plan markting sales hospitals biologists healthcare services oncology COMEX CODIR Leadership team
Roche
Director – French Market Access Haematology, Melanoma, Neurosciences, Rare Diseases and Orphan Drug
PHARMACEUTICALS INDUSTRY
January 2015 - July 2017 (2 years and 6 months)
Paris Area, France
Responsible for the French P&MA strategies in Hematology, Melanoma, Neurosciences, Rare Diseases and Orphan Drugs worth over 280M$ in 2017.
- Gained ASMII for a breakthrough hemophilia drug partly by leveraging patient association group, patient outcomes and putting in place ATU.
- Unlocked full value of melanoma, CLL, multiple sclerosis drugs to achieve ASMR III.
- Led Commission de Transparence audition on follicular lymphoma. - Sought Commission de Transparence early advice on spinal muscular atrophy. - Elaborated 4 oncology pricing deals signed by CEPS.
- Explored alternative funding with private insurers in multiple sclerosis.
Commission de Transparence HAS SMR ASMR CEPS price negotiations price strategy market access reimbursement rare diseases hemophilia SMA melanoma hematology multiple sclerosis global payers KOL orphan drugs ATU early advice funding private insurances mutuelles influence communication CODIR COMEX oncology team manager team development leadership team